Table 1 Characteristics of included studies for the meta-analyses
Study | Year | Country | Method (panel) | endpoint | Patient | Treatment regimens | |
|---|---|---|---|---|---|---|---|
Number | Male/Female | ||||||
Ococks E [29] | 2021 | UK | NextSeq550 Illumina (77 genes) | PFS/OS | 97 | 83/14 | nCT |
Jia R [30] | 2021 | China | Illumina HiSeq3000 (180 genes) | PFS/OS | 24 | 20/4 | Radiation |
Azad TD [31] | 2020 | US | CAPP-seq (607 genes) | PFS/OS | 45 | 30/15 | CRT Surgery |
Davidson M [32] | 2019 | UK | Illumina HiSeq2500 (182 genes) | PFS/OS | 30 | 26/4 | chemotherapy |
Openshaw MR [33] | 2020 | UK | ddPCR (6 genes) | PFS/OS | 40 | 33/7 | chemotherapy |
Maron SB [12] | 2019 | US | Guardant360 test (73 genes) | OS | 183 | NG | Chemotherapy Surgery |
Luo H [34] | 2016 | China | Illumina TruSight Cancer (94 genes) | PFS/OS | 11 | NG | Surgery |
Liu T [35] | 2021 | China | Illumina HiSeq2500 (61 genes) | PFS/OS | 55 | 49/6 | chemotherapy |
Hsieh CC [36] | 2016 | Japan | ddPCR (NG) | PFS/OS | 81 | NG | Chemotherapy Surgery CRT |
van Velzen MJM [16] | 2022 | Netherland | Ion Torrent 2500/500 (NG) | PFS/OS | 72 | 56/16 | chemotherapy |
Hofste LSM [37] | 2022 | Netherland | NextSeq500 Illumina (15 genes) | PFS/OS | 78 | 60/18 | nCRT |
Wang X [38] | 2022 | China | Geneseeq (474 genes) | PFS/OS | 40 | 34/6 | Radiotherapy CRT |
Zhang R [39] | 2020 | China | Illumina HiSeq X Ten (NG) | PFS/OS | 22 | 14/8 | nCT |
Eyck BM [40] | 2022 | Netherland | Ion Torrent S5 GeneStudio Prime System (NG) | PFS/OS | 31 | NG | nCRT |
Morimoto Y [41] | 2023 | Japan | NextSeq Illumina (77 genes) | PFS | 13 | 10/3 | nCT |
Cabalag CS [42] | 2022 | Australia | MiSeq Illumina (48 genes) | PFS/OS | 62 | NG | nCRT |
Yang D [43] | 2022 | China | NGS (1021 genes) | PFS | 10 | 9/1 | nCIT |
Wallander K [44] | 2023 | Sweden | ddPCR (30 genes) | PFS/OS | 10 | 6/4 | CRT |
Fujisawa R [46] | 2021 | Japan | ddPCR (30 genes) | PFS/OS | 42 | NG | nCT |
Mehta R [48] | 2023 | US | Signatera MRD (NG) | OS | 53 | NG | NG |
Lander EM [47] | 2023 | US | Signatera MRD (NG) | OS | 34 | NG | nCRT |
van den Ende T [45] | 2023 | Netherland | NGS (23 genes) | PFS/OS | 111 | NG | nCRT |